Phase 2 Study of Oral Povorcitinib to Treat Moderate to Severe Hidradenitis Suppurativa in Adolescents

What this Trial Is About

Researchers are evaluating the pharmacokinetics, safety, and effectiveness of povorcitinib in adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa. This phase 2 open-label study focuses on this skin condition characterized by painful abscesses and nodules that have persisted for at least three months. Participants must have shown inadequate response or intolerance to conventional systemic treatments. Participants will receive one of two doses of povorcitinib orally as tablets for 54 weeks. This open-label study involves parallel assignment with two experimental groups receiving different doses of the study drug. The long treatment period is designed to assess drug behavior in the body, safety, and clinical response over time. Throughout the study, participants will be regularly monitored for side effects and drug levels in the blood up to 24 weeks. Researchers will assess skin lesion counts, pain scores, and quality of life measures at multiple visits during the 54-week treatment. The study tracks adverse events and detailed pharmacokinetic parameters while evaluating improvements in skin symptoms and overall impact on participants daily lives.

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa